Momelotinib for myelofibrosis.
出版信息
Aust Prescr. 2025 Aug;48(4):149-150. doi: 10.18773/austprescr.2025.031.
Abstract
摘要
相似文献
1
Momelotinib for myelofibrosis.莫洛替尼用于治疗骨髓纤维化。
Aust Prescr. 2025 Aug;48(4):149-150. doi: 10.18773/austprescr.2025.031.
2
Indirect treatment comparison of momelotinib vs fedratinib safety in patients with myelofibrosis.莫洛替尼与费德拉替尼治疗骨髓纤维化患者安全性的间接治疗比较
Future Oncol. 2025 Jul;21(16):2077-2087. doi: 10.1080/14796694.2025.2511564. Epub 2025 Jun 6.
3
Indirect treatment comparisons of momelotinib vs pacritinib safety and anemia outcomes in patients with myelofibrosis.莫洛替尼与帕西替尼治疗骨髓纤维化患者安全性及贫血转归的间接治疗比较
Future Oncol. 2025 Jul;21(16):2067-2075. doi: 10.1080/14796694.2025.2511562. Epub 2025 Jun 6.
4
Momelotinib versus Continued Ruxolitinib or Best Available Therapy in JAK Inhibitor-Experienced Patients with Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-2.莫米松替比 versus 持续芦可替尼或 JAK 抑制剂治疗经验的骨髓纤维化伴贫血患者的最佳可用治疗：SIMPLIFY-2 的亚组分析。
Adv Ther. 2024 Sep;41(9):3722-3735. doi: 10.1007/s12325-024-02928-4. Epub 2024 Jul 11.
5
Momelotinib for the treatment of myelofibrosis with anemia.莫雷洛替尼治疗伴贫血的骨髓纤维化。
Future Oncol. 2022 Jun;18(20):2559-2571. doi: 10.2217/fon-2022-0276. Epub 2022 May 23.
6
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study.莫洛替尼与达那唑治疗有症状的贫血和骨髓纤维化患者的疗效对比（MOMENTUM）：一项国际、双盲、随机、对照3期研究的结果
Lancet. 2023 Jan 28;401(10373):269-280. doi: 10.1016/S0140-6736(22)02036-0.
7
Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.Momelotinib对比最佳可用疗法治疗既往接受过鲁索替尼治疗的骨髓纤维化患者（SIMPLIFY 2）：一项随机、开放标签的3期试验
Lancet Haematol. 2018 Feb;5(2):e73-e81. doi: 10.1016/S2352-3026(17)30237-5. Epub 2017 Dec 20.
8
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study.莫洛替尼与达那唑治疗 JAK 抑制剂预处理的有症状贫血和骨髓纤维化患者（MOMENTUM）：一项国际、双盲、随机 3 期研究的更新分析。
Lancet Haematol. 2023 Sep;10(9):e735-e746. doi: 10.1016/S2352-3026(23)00174-6. Epub 2023 Jul 27.
9
[JAK inhibitors for myelofibrosis: ruxolitinib and momelotinib].用于骨髓纤维化的JAK抑制剂：鲁索替尼和莫洛替尼
Rinsho Ketsueki. 2024;65(8):798-809. doi: 10.11406/rinketsu.65.798.
10
Longitudinal Assessment of Transfusion Intensity in Patients With JAK Inhibitor-Naive or -Experienced Myelofibrosis Treated With Momelotinib.用莫洛替尼治疗的初治或经治JAK抑制剂的骨髓纤维化患者输血强度的纵向评估
Clin Lymphoma Myeloma Leuk. 2025 Mar;25(3):199-211. doi: 10.1016/j.clml.2024.10.001. Epub 2024 Oct 16.
本文引用的文献
1
Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials.Momelotinib 的长期安全性和生存获益：3 期随机对照临床试验的综合分析。
Blood Adv. 2023 Jul 25;7(14):3582-3591. doi: 10.1182/bloodadvances.2022009311.
2
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study.莫洛替尼与达那唑治疗有症状的贫血和骨髓纤维化患者的疗效对比（MOMENTUM）：一项国际、双盲、随机、对照3期研究的结果
Lancet. 2023 Jan 28;401(10373):269-280. doi: 10.1016/S0140-6736(22)02036-0.
3
Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.Momelotinib对比最佳可用疗法治疗既往接受过鲁索替尼治疗的骨髓纤维化患者（SIMPLIFY 2）：一项随机、开放标签的3期试验
Lancet Haematol. 2018 Feb;5(2):e73-e81. doi: 10.1016/S2352-3026(17)30237-5. Epub 2017 Dec 20.
4
SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis.SIMPLIFY-1：一项在初治的骨髓纤维化患者中比较莫洛替尼与芦可替尼的III期随机试验。
J Clin Oncol. 2017 Dec 1;35(34):3844-3850. doi: 10.1200/JCO.2017.73.4418. Epub 2017 Sep 20.
Zotero 插件